Used to treat community-acquired bacterial pneumonia (CABP) in adults. It works by inhibiting bacterial protein synthesis, specifically targeting the 50S ribosomal subunit. Effective against common pathogens like Streptococcus pneumoniae, Staphylococcus aureus, and atypical bacteria such as Legionella pneumophila and Mycoplasma pneumoniae. Available in both intravenous and oral forms, allowing for flexible treatment settings including hospital and outpatient care. Its targeted mechanism helps reduce the risk of cross-resistance with other antibiotic classes.